Skip to content
MarketScale
‹ Back to IndustriesSciences

What Updated Annex 1 Regulations Mean for Sterile Manufacturing Companies in 2023

Over the summer new GMP Annex 1 regulations were released by the FDA and EMA, prompting new changes to become standard protocolin sterile manufacturing companies. By August 2023, the regulations will take effect and companies will have to ensure that they are in compliance with the guidelines set. Discussing this on a new podcast, host…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

Promoted content from Benchmark Products on MarketScale.

By Healthcare · Annex 1Benchmark ProductsCompaniesDisinfecting
Share

Key takeaways

01

Over the summer new GMP Annex 1 regulations were released by the FDA and EMA, prompting new changes to become standard protocolin sterile manufacturing companies.

02

By August 2023, the regulations will take effect and companies will have to ensure that they are in compliance with the guidelines set.

03

Discussing this on a new podcast, host…

Get featured

Want to get featured in MarketScale Sciences?

Create a free MarketScale workspace and get your company's expertise featured across our Sciences coverage. No credit card, no demo required.

Request an invite

Over the summer new GMP Annex 1 regulations were released by the FDA and EMA, prompting new changes to become standard protocolin sterile manufacturing companies. By August 2023, the regulations will take effect and companies will have to ensure that they are in compliance with the guidelines set. Discussing this on a new podcast, host Gabrielle Bejarano talked to Chris White, who is the Global Head of GMP at Adamas Consulting, about what’s new and different, and how manufacturing companies and facilities can meet the regulations of Annex 1.

Of the standout changes, White noted that Annex 1 makes a big distinction between what cleaning is versus what disinfection is, citing that the regulations detail specific differences, and specify that disinfection can only occur after cleaningis complete. Annex 1 emphasizes that there is an “acknowledging that surfaces can only be adequately disinfected once they’re clean —so you have the separation of cleaning versus disinfection,” said White.

He also added that there is a significant emphasis on “material transfer”,which according to White, is “monitoring the materials throughout your facility,and as they are transferred into your more critical areas, how to mitigate the impact of the risk of contamination during that process.”

Evidently, the updated Annex 1 regulations are placing a focus on higher scrutiny in the quality production of sterile manufacturing healthcare products.

A solution to avoiding contamination is the Benchmark Products Suite° line —a series of Ultra-Fiber material products-to help eliminate residue. Leftover residue is quite common in sterile manufacturing companies, and White said that the sources are normally the same culprits, which are disinfectants themselves, sporicidal agents, and even lubricants from equipment.Residues that are not removed can potentially harbor dormant bio burden and impact the effectiveness of disinfectants subsequently applied.

In terms of validating newly established SOPs that comply with Annex 1, Chris suggests choosing a time of facility shut down in an uncleaned area and conducting baseline environmental monitoring sampling. Following a cleaning according to the new SOP, sampling in the same locations is repeated to show an overall reduction in the level of bio burden.

He mentioned that the Benchmark Products Suite line offers“Ultra Fiber technology, which allows you to remove residues to make better surface contact with the surfaces that you’re trying to disinfect, and it also contains the contamination without transferring it from one surface to another.”

Companies that prioritize the cleaning steps and create a dedicated schedule for it will be on track to meet the compliance goals.

Benchmark Products

Part of this channel

Benchmark Products

ISO-certified cleanroom supplies for life science manufacturers.

Visit the channel

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

H
Healthcare

Follow Sciences Insights

Get new expert content in your inbox.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Wall Street is split on Circle: TD Cowen sees 31% upside while Morgan Stanley cuts its target by 64%

Wall Street is split on Circle: TD Cowen sees 31% upside while Morgan Stanley cuts its target by 64%

Wall Street analysts are divided on Circle's valuation prospects. TD Cowen has rated Circle as a buy with a target price of $82, indicating optimism in its potential growth. Meanwhile, Morgan Stanley has significantly lowered its target to $38, questioning the utility of stablecoins.

  • 01TD Cowen set Circle's target price at $82, signaling expected growth.
  • 02Morgan Stanley reduced its target for Circle to $38, citing doubts about stablecoin use.
  • 03There is a significant split among analysts regarding Circle's financial outlook.

Aug 18, 2026

Sony and TSMC's $6.3 billion image-sensor bet signals a new era of chip co-investment

Sony and TSMC's $6.3 billion image-sensor bet signals a new era of chip co-investment

Sony and TSMC have announced a joint investment of $6.3 billion to develop next-generation image-sensor chips. This collaboration is driven by the increasing demand for AI technologies, which is influencing changes in semiconductor supply chains. The initiative is expected to have significant impacts in 2026.

  • 01Sony and TSMC are investing $6.3 billion in next-generation image-sensor chips.
  • 02The investment is motivated by rising demand for AI technologies.
  • 03The partnership is a notable example of co-investment in the semiconductor industry.

Aug 12, 2026

Myrias Optics taps photonics veteran Neil Anderson as CRO to scale flat optics into AI datacenters and AR

Myrias Optics taps photonics veteran Neil Anderson as CRO to scale flat optics into AI datacenters and AR

Myrias Optics has hired Neil Anderson, Ph.D. as the Chief Revenue Officer to spearhead the commercialization of its nanoimprint flat optics platform. The platform is intended for use in AI datacenters, augmented reality (AR), and life sciences applications. Anderson's experience in photonics is expected to aid Myrias Optics in expanding its market presence in these sectors.

  • 01Myrias Optics appointed Neil Anderson, Ph.D. as CRO to lead the commercialization of its technology.
  • 02The company focuses on nanoimprint flat optics for AI datacenters, AR, and life sciences.
  • 03Neil Anderson brings extensive photonics expertise to support Myrias Optics' growth.

Jul 31, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

H
Healthcare

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512